Both mandates are for a three-year period.
“The PRAC is set to play a pivotal role in delivering the public health benefits of the new European pharmacovigilance legislation,” said Dr Raine on accepting her election. “My ambition is to make sure that this unique opportunity to strengthen public health protection is fully realised for the benefit of all citizens in the European Union. The new legislation provides powerful tools to strengthen the protection of public health in Europe and the effective use of these tools will depend on clarity of vision, strong leadership, sound scientific judgement and excellent communication by the PRAC.”
Over the course of her career, Dr Raine has made outstanding contributions towards delivering a world-class EU pharmacovigilance system. Together, she and Dr Spooner bring a wealth of experience in medicine, pharmacy, regulation of medicines and public health protection through pharmaco-vigilance and risk management of medicines to their new roles.
New levels of transparency
The PRAC operates with a high level of transparency. The agendas for the meetings will be systematically published on the Agency's website ahead of the meeting and the detailed outcome will be made available in meeting minutes, which will be published after their adoption at the following PRAC meeting.
“The PRAC is set to play a pivotal role in delivering the public health benefits of the new European pharmacovigilance legislation,” said Dr Raine on accepting her election. “My ambition is to make sure that this unique opportunity to strengthen public health protection is fully realised for the benefit of all citizens in the European Union. The new legislation provides powerful tools to strengthen the protection of public health in Europe and the effective use of these tools will depend on clarity of vision, strong leadership, sound scientific judgement and excellent communication by the PRAC.”
Over the course of her career, Dr Raine has made outstanding contributions towards delivering a world-class EU pharmacovigilance system. Together, she and Dr Spooner bring a wealth of experience in medicine, pharmacy, regulation of medicines and public health protection through pharmaco-vigilance and risk management of medicines to their new roles.
New levels of transparency
The PRAC operates with a high level of transparency. The agendas for the meetings will be systematically published on the Agency's website ahead of the meeting and the detailed outcome will be made available in meeting minutes, which will be published after their adoption at the following PRAC meeting.
Companies in this article
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
